Skip to main content

Market Overview

Chembio Diagnostics' Stock Suddenly Got Interesting


Shares of biotech Chembio Diagnostics Inc (NASDAQ: CEMI) got a dramatic boost in the arm Monday morning.

The Medford, New York-based firm announced a partnership with Integrated BioTherapeutics, Inc to develop and continue to maintain "exclusive rights to any POC (Point of Care) product developed through (their) agreement."

Chembio will combine its patented DPP(R) technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness.

At time of writing, shres were trading at a robust pace. Volume was up over 600 percent, when compared to Chembio's average three-month trading volume.

The stock was recently up 14.5 percent at $4.56, from previous close of $3.99 per share.


Related Articles (CEMI)

View Comments and Join the Discussion!

Posted-In: News Small Cap Events Intraday Update Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at